the benefit of monotherapy with high-dose mtx for adjuvant treatment of osteosarcoma remains questionable , since 6 of 8 patients with primary osteosarcoma developed pulmonary metastases within 4-12 months ( median 5 months ) , 2 have been disease-free and alive for 25 and 53 months .
C0025677
mtx
C0029463
osteosarcoma